browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
1d374959-7ae3-4071-963f-31e5e0e3ffaf
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 14:06:10
Income (reported)
$60,000
Expenses (reported)
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

DLA PIPER LLP (US)

Law firm.

Contact
WILLIAM MINOR
Phone
+1 202-799-4312
Address
zip:20004, city:Washington, state:DC, street:500 8th Street, NW
Client

BIOTECHNOLOGY INNOVATION ORGANIZATION

Advocacy organization for the biotechnology industry.

State
DC
Country
US
Effective date
2025-04-01
Issues lobbied + lobbyists (4)

MMM — Medicare/Medicaid

Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.

Lobbyists:

Government entities lobbied: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

PHA — Pharmacy

340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.

Lobbyists:

Government entities lobbied: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

MED — Medical/Disease Research/Clinical Labs

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.

Lobbyists:

Government entities lobbied: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.

Lobbyists:

Government entities lobbied: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.